Verastem, Inc.
Verastem, Inc. (VSTM): 6 pipeline candidates · 2 upcoming catalysts · ~11 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.8 months
D/E 1.79 · 13% dilution
Lead: Approved
6 candidates
2 upcoming, next in ~1697d
0 buys · 5 sells (180d)
A transparent, data-derived signal for Verastem, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$351.5M
Cash
$165.8M
Quarterly Burn
$52.1M
Runway
10.8 mo
Revenue
$18.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| avmapki | Approved |
| avmapki fakzynja co-pack | Approved |
| avutometinib | Phase 3 |
| cetuximab | Phase 2 |
| defactinib | Phase 3 |
| vs-7375 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
154
Total value held
$396.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,645,540 | $35.2M |
| rtw investments, lp | 6,576,306 | $34.9M |
| blackrock, inc. | 6,194,925 | $32.8M |
| deep track capital, lp | 5,740,850 | $30.4M |
| armistice capital, llc | 4,592,000 | $24.3M |
| state street corp | 3,516,651 | $18.6M |
| millennium management llc | 2,411,965 | $12.8M |
| citadel advisors llc | 2,376,269 | $12.6M |
| morgan stanley | 2,247,273 | $11.9M |
| rosalind advisors, inc. | 2,138,475 | $11.3M |
Showing top 10 of 154 institutional holders of Verastem, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Verastem, Inc.'s pipeline?
Verastem, Inc. (VSTM) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Verastem, Inc.'s lead drug candidate?
Verastem, Inc.'s most advanced tracked candidate is avmapki (Approved) for KRAS mt LGSOC.
What is Verastem, Inc.'s next catalyst?
Verastem, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver" — expected February 9, 2031.
What is Verastem, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Verastem, Inc. has approximately 10.8 months of cash runway.
What is Verastem, Inc.'s market capitalization?
Verastem, Inc.'s market capitalization is approximately $351.5M.
Get the full picture on Verastem, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.